[0001] The present invention relates to cleaning and passivating treatments for metals.
More particularly, the present invention relates to cleaning and passivating treatments
for metals which are essentially free of amines, alkanolamines, and phosphates. The
aqueous treatments of the present invention comprise amphoteric surfactants which
were found to provide an excellent passivating film on ferrous surfaces. The amphoteric
surfactants of the present invention are caprylic acid derivatives of imidazoline
compounds.
[0002] "In process" cleaners are employed in the metal treatment industry to clean and passivate
a metal surface. These types of aqueous cleaners are typically based on organic rust-proofing
or passivating agents such as combinations of alkanolamines and fatty acids, surfactants,
anti-foam agents and/or phosphonates and possibly biocides and builders. In order
to passivate a metal surface to prevent rusting during process breaks and storage,
appropriate additives are used. Cleaning and passivating agents which inhibit the
corrosion of ferrous metal surfaces contain for example alkali nitrites, alkanolamines,
soaps and benzoates.
[0003] Clean and passivate treatments are typically employed in applications which require
good cleaning and temporary metal passivation. Treated parts may need to remain rust-free,
while exposed in the manufacturing plant for from several hours up to 30 days. In
order to maintain their rust prevention ability, these cleaners are not rinsed. Current
commercial cleaners typically employ alkanolamines such as monoethanolamine, diethanolamine
or triethanolamine as a passivating agent for ferrous surfaces. The alkanolamine component
inhibits flash rusting of ferrous iron parts during line stops or storage. Typical
cleaners also will include surfactants such as glycol ether compounds and phosphonate
compounds which aid in cleaning of the parts. For example, U.S. Patent No. 4,578,208
which issued to Geke et al. discloses a cleaning and/or passivating composition and
process which employs a phosphoric acid ester, an alkanolamine and a surfactant and
optionally builders, non-ferrous metal inhibitors and biocides.
[0004] Currently, environmental objections are being raised concerning the use of alkanolamines,
phosphates and glycol ethers as raw materials for industrial processes.
SUMMARY OF THE INVENTION
[0005] The present inventors discovered that a specific class of amphoteric surfactants
provides excellent passivation of ferrous metals when substituted for alkanolamines.
The use of amphoteric surfactants in accordance with the present invention obviates
the need for amines, alkanolamines, phosphates and other currently environmentally
undesirable materials in clean and passivate formulations. The inventors found that
caprylic acid derivatives of imidazoline compounds provide efficacious passivation
of ferrous metal surfaces. The treatment solution of the present invention is substantially
free of amines, alkanolamines, and phosphates. By substantially free, it is meant
that these materials are not intentionally added as active components of the treatment
solution. The preferred treatment solution also includes small quantities of a borate
ion and sodium molybdate. These compounds were found to allow reductions in the concentration
of the amphoteric surfactant component without adversely affecting efficacy. In addition,
a defoamer such as a nonionic surfactant may be desirable in spray applications.
DESCRIPTION OF THE PREFERRED EMBODIMENT
[0006] The present inventors discovered a clean and passivate treatment formulation for
use in treating ferrous metal surfaces which is substantially free of amines, alkanolamines,
and phosphates. The clean and passivate formulation of the present invention is an
aqueous solution of a caprylic acid derivative of an imidazoline. The formulation
preferably also includes a borate ion, sodium molybdate and a nonionic surfactant
defoamer. The inventors found that aqueous solutions of caprylic acid derivatives
of an imidazoline provide effective rust protection. It was further discovered that
when such amphoteric surfactants were used in combination with a borate ion and sodium
molybdate significantly lower concentrations of the amphoteric surfactant could be
employed with good rust inhibition results. The borate ion may be provided by a borate
salt or by boric acid.
[0007] The formulation of the present invention includes amphoteric surfactants which are
caprylic acid derivatives of an imidazoline compound. The surfactants are present
in the treatment solution at concentrations of from about 0.05% up to about 5% by
weight. Examples of commercially available amphoteric surfactants include Monateric
Cy-Na 50%, a sodium salt of 2-caprylic-1 (ethyl beta oxypropanoic acid) imidazoline;
Monateric LF-100, a Cā
āā methyl alkyl imidazoline; Monateric LF-Na 50, a sodium salt
of LF-100 but 50% active; Monateric CYA-50, a capryl ampho-propionate; Monateric 1000,
a capryl amphopropionate; and Miranol JAS concentrate which is a carboxylate derivative
of capryl imidazoline. Miranol is a trademark of Rhone-Poulenc and Monateric is a
trademark of Mona Industries. Amphopropionate is another name for imidazoline.
[0008] When a caprylic acid derivative of an imidazoline is used alone, the preferred treatment
concentration is about 5% by weight. When a caprylic acid derivative of an imidazoline
is employed in the preferred combination which includes a borate ion (such as sodium
metaborate octahydrate) and a molybdate ion (such as sodium molybdate), the concentration
of the surfactant can be decreased to about 0.1 to 0.3% by weight. The preferred concentration
of sodium molybdate is from about 0.1 to 0.5% by weight. The preferred concentration
of sodium metaborate octahydrate is from about 0.1 to 0.5% by weight. The ratio of
imidazoline to borate ion is from about 1:0.4 to 1.5 and the ratio of molybdate ion
to imidazoline and borate ion is more than about 1:4
[0009] The clean and passivate formulation of the present invention is typically supplied
in two concentrate packages which are diluted and mixed prior to application. The
first comprises the caprylic derivative of imidazoline compound; sodium molybdate
and sodium metaborate octahydrate in deionized water. The second package comprises
a nonionic surfactant defoaming agent.
[0010] Efficacy of the treatment solution of the present invention was evaluated in a chip
test evaluation. The test involved placing 4 g of cast iron chips on a filter paper
in a plastic weighing dish, adding 50 ml of the test solution, allowing the solution
to stand for 24 hours. The filter paper is rinsed with tap water and examined for
rust spots. Refer to ASTM D4627-92.
[0011] The effectiveness of the composition and method of the present invention is demonstrated
by the following examples which are provided as illustrative and are not intended
to limit the scope of the invention as set forth in the claims.
Example 1
[0012] A variety of amphoteric surfactants which are imidazoline compounds were tested in
the above manner. Table I summarizes the results.

[0013] The data in Table I shows that amphoteric surfactants which are caprylic acid derivatives
of an imidazoline will provide chip protection while a C12-C14 fatty acid derivative
of an imidazoline (Monateric CEM-38) does not provide such protection.
Example 2
[0014] The above described chip test was employed to evaluate various treatment concentrations
of the surfactant, the borate, and the molybdate. Table II summarizes the results.

[0015] The data in Table II shows that efficacious results are obtained at a relatively
low treatment concentration with the preferred combination of the present invention.
Example 3
[0016] Monateric LF-Na 50 was tested in a treatment solution including sodium metaborate
octahydrate, sodium molybdate and Macol LF 110 (a nonionic polyoxyalkylated aliphatic
ether available from PPG Industries, Inc. which was added as a defoamer). The addition
of the borate and molybdate was found to allow excellent passivation, i.e., no chip
rusting, in the above described chip test with a relatively low concentration of amphoteric
surfactant. The treatment solution tested is set out in Table III in weight percent.
TABLE III
Sodium meta borate octahydrate |
0.5% |
Sodium molybdate |
0.1% |
Monateric LF-Na-50 |
0.1% as 100% actives |
Macol LF 110 |
0.04% |
Example 4
[0017] The presence of Macol LF 110 in the composition of Example 3 is included to inhibit
foaming tendencies of the imidazoline surfactant. The presence of the defoamer does
not effect the passivating activity of the imidazoline surfactant. Table IV summarizes
chip testing as described above of a treatment in accordance with the present invention
with and without a nonionic polyoxyalkylated aliphatic ether defoamer (Macol LF 110
available from PPG Industries, Inc.).
TABLE IV
Composition (grams/100 grams) |
Chip Test |
Monateric LF Na-50 |
NaBO2.8H20 |
Sodium Molybdate |
Water |
Macol LF 110 |
|
1. 0.075 |
0.37 |
0.075 |
99.48 |
----- |
no rust spots |
2. 0.075 |
0.37 |
0.075 |
99.44 |
0.04 |
no rust spots |
3. 0.10 |
0.50 |
0.10 |
99.30 |
----- |
no rust spots |
4. 0.10 |
0.50 |
0.10 |
99.26 |
0.04 |
no rust spots |
[0018] For economies of shipping and handling, the treatment solution of the present invention
is preferably supplied as a concentrate which is diluted with deionized water to form
a working bath. A preferred concentrate comprises 12.5% sodium metaborate octahydrate,
2.5% sodium molybdate, 5.0% Monateric LF-Na 50 and 80% deionized water. The Macol
LF 110 defoamer is supplied separately. A 4% v/v dilution of the preferred concentrate
with 0.04% v/v of Macol LF 110 results in the treatment solution described in Example
3. This preferred treatment solution has been found to be effective when diluted with
DI, soft or hard water.
[0019] While the present invention has been described with respect to particular embodiments
thereof, it is apparent that numerous other forms and modifications of this invention
will be obvious to those skilled in the art. The appended claims and this invention
generally should be construed to cover all such obvious forms and modifications which
are within the true spirit and scope of the present invention.
1. A cleaning and passivating treatment solution for ferrous metal surface comprising
an essentially amine; alkanol amine and phosphate free aqueous solution of (a) from
about 0.05 to 5.0% by weight of a caprylic acid derivative of imidazoline amphoteric
surfactant, (b) a borate ion and (c) a molybdate ion wherein the ratio of imidazoline
amphoteric surfactant to borate ion is from about 1:0.4 to 1:5 and the ratio of sodium
molybdate to imidazoline amphoteric surfactant and borate ion is more than about 1:4.
2. A treatment solution as claimed in claim 1, wherein said borate ion is provided by
sodium metaborate octahydrate.
3. A treatment solution as claimed in claim 1 or 2, wherein said molybdate ion is provided
by sodium molybdate.
4. A treatment solution as claimed in any one of the preceding claims, wherein said treatment
solution further includes a nonionic surfactant defoaming agent.
5. A method of cleaning and passivating a ferrous metal surface comprising contacting
the ferrous metal surface with an aqueous treatment solution comprising (a) from about
0.05 to 5.0% by weight of a caprylic acid derivative of imidazoline amphoteric surfactant,
(b) a borate ion, and (c) a molybdate ion wherein the ratio of imidazoline amphoteric
surfactant to borate ion is from about 1:0.4 to 1:5 and the ratio of sodium molybdate
to imidazoline amphoteric surfactant and borate ion is more than about 1:4.
6. A method as claimed in claim 5, wherein said borate ion is provided by sodium metaborate
octahydrate.
7. A method as claimed in claim 5 or 6, wherein said molybdate ion is provided by sodium
molybdate.
8. A method as claimed in any of claims 5 to 7, wherein said treatment solution further
includes a nonionic surfactant defoaming agent.